For example, the company has ongoing late-stage clinical trials examining Cobenfy's potential in treating Alzheimer's disease ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Bristol Myers Squibb was in a strong position in Q2 FY2024 ... in neuropsychiatry and broadening of its indications in Alzheimer's and bipolar disorder represent growth opportunities.

Bristol Myers’ $1.5 billion restructuring initiative ... Beyond schizophrenia, BMS’ ADEPT program for Cobenfy in Alzheimer’s disease psychosis could read out in 2026. And the company plans ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... These drugs are also being tested for Alzheimer’s and other conditions commonly linked to obesity.